Screener
MaxCyte MXCT Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $15.04M-1.2% | $14.56M-37.8% | $20.07M-28.0% | $12.97M-64.9% | $15.23M-59.4% | ||
| $90.65M-18.6% | $92.3M-19.7% | $82.98M-34.5% | $92.76M-20.6% | $111.34M-7.1% | ||
| $3.92M-31.8% | $4.25M-23.1% | $3.5M-25.2% | $8.31M+82.1% | $5.75M+25.6% | ||
| $7.8M-1.7% | $7.63M-7.8% | $7.55M-15.3% | $7.61M-26.8% | $7.93M-28.9% | ||
| $121.27M-15.3% | $122.94M-21.1% | $118.37M-31.1% | $124.65M-27.9% | $143.22M-18.5% | ||
| $14.9M-23.2% | $16.64M-16.5% | $17.53M-11.0% | $18.62M-11.2% | $19.4M-10.7% | ||
| $766K+20.1% | $783K+57.2% | $650K— | $667K— | $638K— | ||
| $184.67M-16.0% | $194.47M-15.4% | $202.51M-15.4% | $213.48M-14.1% | $219.75M-12.6% | ||
| $1.73M+43.3% | $1.2M-47.5% | $1.4M+3.2% | $1.29M-31.0% | $1.21M+27.0% | ||
| $2.46M-6.7% | $3.27M-21.1% | $3.6M-31.5% | $5.2M-21.9% | $2.64M-21.6% | ||
| $9.9M-14.4% | $10.21M-19.8% | $14.27M-9.6% | $16.1M-8.6% | $11.56M-5.9% | ||
| $25.92M-10.7% | $26.59M-13.0% | $31.02M-6.6% | $33.2M-6.0% | $29.03M-4.0% | ||
| $1.07M+0.8% | $1.07M+0.8% | $1.07M+1.0% | $1.07M+1.2% | $1.07M+1.7% | ||
| -$275.11M-14.9% | -$266.23M-17.2% | -$261.48M-20.6% | -$251.89M-22.1% | -$239.47M-23.0% | ||
| $158.75M-16.8% | $167.89M-15.8% | $171.49M-16.9% | $180.28M-15.5% | $190.72M-13.8% | ||
| $184.67M-16.0% | $194.47M-15.4% | $202.51M-15.4% | $213.48M-14.1% | $219.75M-12.6% |
FAQ
- What are MaxCyte's total assets?
- MaxCyte (MXCT) holds $184.7M in total assets, down 16.0% year over year.
- How much debt does MaxCyte have?
- MaxCyte carries $17.3M in total debt against $158.8M of shareholders' equity, a debt-to-equity ratio of 0.11.
- How much cash does MaxCyte have?
- MaxCyte holds $15.0M in cash and equivalents.
- Can MaxCyte cover its short-term obligations?
- Its current ratio is 12.26 — current assets exceed current liabilities.
- Where does MaxCyte's balance sheet data come from?
- Every line is extracted from MaxCyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
